BioLife Solutions, Inc. $BLFS Shares Bought by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its stake in BioLife Solutions by 5.4% during Q1, owning 286,893 shares valued at approximately $6.55 million.
• BioLife Solutions reported a quarterly loss of ($0.33) earnings per share, missing the consensus estimate by ($0.31), despite a revenue of $25.42 million.
• Major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares for $23.80 each, reducing their position by 11.48% to maintain ownership of 7,707,165 shares.

Russell Investments Group Ltd. increased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 5.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 286,893 shares of the medical equipment provider's stock after buying an additional 14,631 shares during the period. Russell Investments Group Ltd. owned about 0.60% of BioLife Solutions worth $6,553,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the fourth quarter worth approximately $31,000. US Bancorp DE grew its holdings in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,528 shares during the last quarter. GAMMA Investing LLC grew its holdings in BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the last quarter. Avantax Advisory Services Inc. grew its holdings in BioLife Solutions by 16.0% in the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock worth $207,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new position in BioLife Solutions in the fourth quarter worth $254,000. Institutional investors own 93.24% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Stephens assumed coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price target on the stock. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Finally, Zacks Research raised shares of BioLife Solutions to a "strong-buy" rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, BioLife Solutions has an average rating of "Buy" and an average target price of $31.29.

Insider Buying and Selling at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the sale, the insider directly owned 6,707,165 shares of the company's stock, valued at $163,654,826. The trade was a 6.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 2,008,831 shares of company stock worth $47,499,658 over the last 90 days. 2.20% of the stock is owned by insiders.

BioLife Solutions Price Performance

Shares of BLFS remained flat at $25.65 during trading hours on Tuesday. 541,408 shares of the stock were exchanged, compared to its average volume of 576,652. The company has a market capitalization of $1.23 billion, a PE ratio of -213.73 and a beta of 1.76. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.55. The stock has a 50-day simple moving average of $22.47 and a two-hundred day simple moving average of $23.38.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.